Showing results (251-260 of 608) with videos related to

Sort By:
Pageof 61
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 17, 2022
Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarateJennifer Lyons, Richard Hughes, Kerry McCarthy, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 12, 2025
Cortico-hippocampal molecular characterization in rat model of multiple sclerosis: Neuroprotective mechanisms of Nigella sativa oilRhoda Mama Kolo, Chijoke Bethel Ehirim, Damilola Opeadua Olabiyi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 9, 2025
Semantic networks in relapsing-remitting multiple sclerosis exhibit reduced efficiency, interconnectivity, and flexibilitySophia Lall, Jennifer Pardo, Joshua Sandry
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 14, 2020
Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinicDavid Jure Hunt, Anthony Traboulsee
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 3, 2020
Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onsetSiew Mei Yap, Mary Dillon, Rachel K Crowley, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 2, 2022
A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapseBenjamin M Greenberg, James D Bowen, Enrique Alvarez, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 2, 2021
High prevalence of fatigue in contemporary patients with multiple sclerosisLine Broch, Cecilia Smith Simonsen, Heidi Øyen Flemmen, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 13, 2025
Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trialNaghmeh Abbasi Kasbi, Ali Rezaei, Reyhaneh Montazeri, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2025
Epilepsy in MS and its association with cognitive and psychological burdenValeria Pozzilli, Carla Tortorella, Luca Prosperini, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 7, 2025
Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosisShiv Saidha, John Kramer, Brandon Brown, et al.
Pageof 61